AbOliGo is a biotechnology company that develops fast, reproducible antibody-oligonucleotide conjugates (AOCs) for multiplexed protein analysis, proteomics, and spatial biology. Their proprietary conjugation platform produces high-quality AOCs at microgram to milligram scale with delivery in just three days, enabling researchers to convert any antibody into a functional conjugate for multiomic workflows.
- Biotechnology
- Drug Discovery & Therapeutics
Funding
Funding not disclosed
Founders
Product
Problem
Despite over 7 million research-use-only antibodies available on the market, fewer than 0.1% are offered as antibody-oligonucleotide conjugates (AOCs), severely limiting scientific discovery in multiplexed protein analysis, proteomics, and spatial biology. Researchers face significant bottlenecks accessing high-quality AOCs due to slow, irreproducible, and difficult-to-scale conjugation methods that restrict the use of these critical reagents.
Solution
AbOliGo provides a proprietary conjugation platform that delivers fast, reproducible, and customizable antibody-oligonucleotide conjugates for spatial biology, proteomics, and single-cell workflows. The platform enables production at microgram to milligram scale, with quantitative QC release criteria ensuring batch consistency and a manufacturing-to-delivery timeline of just three days from antibody to conjugate. AbOliGo's technology supports miniaturized process development using as little as 10 µg of antibody input, making rare and costly antibodies accessible, while automated manufacturing increases throughput and precision. The company also offers a searchable catalog of over 3,000 AOC products, including conjugates targeting phospho-proteins such as Phospho-Tau-T231 and Phospho-MDM2-S166, with custom conjugation services available.
Target Audience
Primary customers are researchers in spatial biology, proteomics, and single-cell multiomics who need high-quality, customizable AOCs for multiplexed protein analysis, as well as translational labs requiring reproducible conjugates for clinical research applications.
Features
- Proprietary conjugation methodology enabling AOC production at microgram to milligram scale with quantitative QC release criteria for batch consistency
- Miniaturized process development using as little as 10 µg of antibody input for rare and costly antibodies
- Automated manufacturing platform increasing throughput, precision, and reproducibility
- Catalog of over 3,000 antibody-oligo conjugates, including phospho-specific antibodies validated for immunofluorescence, ELISA, IHC, and proximity ligation assays
- Dual gel staining (DNA and protein) analytical characterization confirming both antibody and oligo content with effective post-conjugation purification
- AI-powered panel design platform in development for multiplex panel optimization